Market Place
Sourcing Support
Verastem Oncology Announces Late Breaking And Regular Abstracts
17 Mar 2026 //
BUSSINESSWIRE
Verastem Oncology Reports Q4 and Full Year 2025 Financial Results
04 Mar 2026 //
BUSSINESSWIRE
Verastem Oncology Outlines 2026 Strategy For RAS/MAPK Cancer
04 Feb 2026 //
BUSINESSWIRE
Verastem Oncology Announces Inducement Grants Under Nasdaq Rules
12 Jan 2026 //
BUSINESSWIRE
Verastem Oncology Unveils Plan To Speed Up Growth Phase
15 Dec 2025 //
BUSINESSWIRE
Verastem Oncology Announces Proposed Offering of Common Stock
13 Nov 2025 //
BUSINESSWIRE
Verastem Oncology To Release Q3 2025 Financial Results On Nov 4
23 Oct 2025 //
BUSINESSWIRE
Verastem Oncology Issues Inducement Grants Per Nasdaq LR
07 Oct 2025 //
BUSINESSWIRE
Verastem Oncology to Present at Upcoming Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Verastem Oncology`s Q2 2025 Financial Results Due August 7
29 Jul 2025 //
BUSINESSWIRE
Verastem Grants Inducement Awards Under Nasdaq Rule 5635(c)(4)
08 Jul 2025 //
BUSINESSWIRE
Verastem Publishes Ph 1 Avutometinib Data in Nature Med
30 Jun 2025 //
BUSINESSWIRE
Verastem Shares KRAS G12D Ph1 Data From GenFleet In China
02 Jun 2025 //
BUSINESSWIRE
Verastem Oncology to Present at Jefferies Healthcare Conference
28 May 2025 //
BUSINESSWIRE
Verastem Oncology Reports Q1 2025 Financial Results & Update
13 May 2025 //
BUSINESSWIRE
Onco360 Chosen as National Specialty Pharmacy for AVMAPKI AKZY
12 May 2025 //
GLOBENEWSWIRE
Verastem Oncology to Present at Upcoming Investor Conferences
01 May 2025 //
BUSINESSWIRE
Verastem Oncology Announces $75 million Private Placement
25 Apr 2025 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
07 Apr 2025 //
BUSINESSWIRE
Verastem Oncology Announces Presentations on RAS/MAPK at AACR 2025
25 Mar 2025 //
BUSINESSWIRE
Verastem Oncology Reports Q4 and Full Year 2024 Financial Results
20 Mar 2025 //
BUSINESSWIRE
Verastem To Present Data At Society Of Gynecologic Oncology 2025
20 Feb 2025 //
BUSINESSWIRE
Verastem Outlines 2025 Goals For RAS/MAPK Cancer Pipeline
23 Jan 2025 //
BUSINESSWIRE
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
15 Jan 2025 //
BUSINESSWIRE
Verastem Licenses VS-7375, Updates KRAS G12D Ph 1 Study in China
14 Jan 2025 //
BUSINESSWIRE
Verastem Announces KRAS Ovarian Cancer Launch, Debt Refinancing
13 Jan 2025 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
08 Jan 2025 //
BUSINESSWIRE
Verastem Announces FDA Acceptance for Avutometinib in Ovarian Cancer
30 Dec 2024 //
BUSINESSWIRE
Verastem Provides Update on RAMP 203 Trial in KRAS G12C Lung Cancer
18 Dec 2024 //
BUSINESSWIRE
Verastem to Present at Evercore ISI HealthCONx Conference
26 Nov 2024 //
BUSINESSWIRE
Verastem Oncology Reports Q3 2024 Results & Business Updates
06 Nov 2024 //
BUSINESSWIRE
Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer
31 Oct 2024 //
BUSINESSWIRE
Verastem Presents Updated Data For Avutometinib In Ovarian Cancer
17 Oct 2024 //
BUSINESSWIRE
Verastem Announces RAMP 201 Data Oral Presentation At IGCS 2024
09 Oct 2024 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
07 Oct 2024 //
BUSINESSWIRE
Verastem To Present RAMP 201 Data At IGCS 2024 Meeting
10 Sep 2024 //
BUSINESSWIRE
Verastem Oncology Reports Q2 2024 Results And Business Updates
08 Aug 2024 //
BUSINESSWIRE
Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer
29 Jul 2024 //
BUSINESSWIRE
Verastem Announces Proposed Public Offering Of Stock And Warrants
23 Jul 2024 //
BUSINESSWIRE
Verastem Prices $55M Public Offering Of Stock And Warrants
23 Jul 2024 //
BUSINESSWIRE
Verastem Doses First Patient With GFH375/VS-7375 In China Phase 1/2 Trial
12 Jul 2024 //
BUSINESSWIRE
Verastem Oncology Grants Inducement Awards Under Nasdaq Rule 5635(c)(4)
08 Jul 2024 //
BUSINESSWIRE
Verastem Oncology Added To Russell 3000 And Microcap Indexes
01 Jul 2024 //
BUSINESSWIRE
Verastem`s begins rolling sub of NDA to USFDA of avutometinib & defactinib combo
28 May 2024 //
PHARMABIZ
ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success
25 May 2024 //
CLINICALTRIALSARENA
Verastem Nda Initiation: Avutometinib Defactinib Combo Rolling Submission
24 May 2024 //
BUSINESSWIRE
Verastem Pancreatic Interim Positive: Avutometinib Defactinib Chemo Combo
23 May 2024 //
BUSINESSWIRE
Verastem Oncology Q1 2024 Financials, Business Update
09 May 2024 //
BUSINESSWIRE
Verastem Oncology At RBC Healthcare Conference
07 May 2024 //
BUSINESSWIRE
Verastem Oncology Appoints John Hayslip As Chief Medical Officer
18 Apr 2024 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 //
BUSINESSWIRE
Results Reveal Negative Impact on Well-Being for People Living with LGSOC
18 Mar 2024 //
BUSINESSWIRE
Verastem survey shows toll rare cancer takes on well-being
18 Mar 2024 //
FIERCE PHARMA
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
BUSINESSWIRE
Verastem Announces Multiple Oral Presentations at SGO 2024 Annual Meeting
11 Mar 2024 //
BUSINESSWIRE
Verastem Oncology Outlines Key 2024 Strategic Priorities
29 Jan 2024 //
BUSINESSWIRE
Verastem Granted Fast Track Designation for Avutometinib and Sotorasib
18 Jan 2024 //
BUSINESSWIRE
Verastem Oncology to Participate in B. Riley Securities 4th Oncology Conference
11 Jan 2024 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
BUSINESSWIRE
